Close Menu

technology commercialization

The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.

The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

The company recently inked deals with Mammoth Biosciences and Rutgers University to license a protein discovery platform and gene editing technology.

Illumina, Twist Bioscience, and DNA Script are among the private sector collaborators of the groups receiving funds to develop technology platforms.

The "augmented intelligence" startup applies machine learning and contextual language processing to make sense of multi-omics datasets and inform drug discovery.

A new sequencing-based method developed by Duke University's Kate Meyer is one of several that can detect RNA methylation without the use of antibodies.

Seattle-based Adaptive will develop in vitro diagnostic test kits for distribution, which will run on Illumina's NextSeq 550 Dx system.

A study published this week describing the new approach shows higher resolution than an earlier method that 10x Genomics is commercializing.

The company, which is also backed by Health Innovation Manchester, aims to expedite the commercialization of biomarkers into new diagnostic tests.

The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.